Clear Street on Dianthus Therapeutics (DNTH): 'We view these data as de-risking'

March 9, 2026 7:28 AM

Clear Street analyst Bill Maughan reiterated a Buy rating and $100.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found